15
Sep
2022
Third Harmonic Revives IPO Market, PDUFA Deadline Nears, & Pfizer Aims mRNA at Flu
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Sep
2022
Pretzel Gets $72.5M for Gene Editing & Small Molecules Against Mitochondrial Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2022
Amylyx’s ALS Surprise, Regeneron’s Eye Franchise Win & Roche Buys Good
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2022
Designing Gene Circuits For Cell Therapies: Tim Lu on The Long Run
Today’s guest on The Long Run is Tim Lu. Tim is the co-founder and CEO of South San Francisco-based Senti Biosciences. Senti is working to develop gene circuits for cell therapies. This is about reprogramming cell therapies with precise genetic instructions on what to do in certain circumstances. The code essentially can tell the cell to kill tumor cells with... Read More
7
Sep
2022
Seek Truth and Kill Quickly: Learning the Hard Way About Biotech Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Sep
2022
FDA Clears Bivalent Vaccines, Novo Buys Forma, & Novartis R&D Chief Moves On
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Aug
2022
Arch Bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2022
A Leap for Open Science, Fauci Exits NIH, & Bivalent Boosters on Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2022
Startup Snapshots: Aktis Fetches $84M for Radiopharmaceuticals, 3T Gets $40M for Antigen Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Aug
2022
A Life in Autoimmune Drug Discovery: Jo Viney on The Long Run
Today’s guest on The Long Run is Jo Viney. She is the CEO of Watertown, Mass.-based Seismic Therapeutic. Seismic is working to discover biologic drugs for autoimmune disease. It aims to speed up the process by using machine learning on key aspects – starting with structural biology and including engineering of the protein drugs themselves. Jo has a long track... Read More
11
Aug
2022
Karuna’s Schizophrenia Advance, FDA Clears HER2-Low Drug, & Pfizer Buys GBT
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2022
Assembling Accurate Genomes and Interactomes: Ivan Liachko on The Long Run
Today’s guest on The Long Run is Ivan Liachko. Ivan the founder and CEO of Seattle-based Phase Genomics. First off, Ivan is originally from Kiev, Ukraine. He came with his family to the US at the age of 11, around the time of the fall of the old Soviet Union. When Russia invaded Ukraine back in February, he spoke up... Read More
4
Aug
2022
Alnylam’s Big Day, Amgen Buys ChemoCentryx & a Borisy Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2022
ElevateBio, Boston Children’s Form Startup to Turn iPSCs Into Mature T-cells for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Aug
2022
A Glimpse Into the Adjacent Possible: Incorporating AI Into Medical Science
The implementation of emerging technologies requires front-line users to figure out what to do with the technology – how to adapt the technology to the problems users are actively trying to solve. The most impactful use cases often are not immediately obvious – for example, Edison envisioned the phonograph would be predominantly used to record wills. Moreover, effective adoption typically requires... Read More
26
Jul
2022
The New Frontier of Cytokine Therapies: Engineered Selectivity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jul
2022
CAMP4 Raises $100M to Drug ‘the Dark Side of the Genome’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jul
2022
James Mutamba of Arrakis on Negotiating a Big Amgen Deal at Warp Speed
James Mutamba is the chief business officer of Waltham, Mass.-based Arrakis Therapeutics. It’s a biotech developing small molecules against RNA targets. Arrakis struck its first major pharma partnership in 2020 with Roche. During the JP Morgan Healthcare Conference this past January, Arrakis announced another multi-target collaboration with Amgen to discover and develop small molecule RNA degraders, a new drug class... Read More
14
Jul
2022
Novavax Cleared, Verve’s Gene Editing Milestone, & Third Rock Reaches Out
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jul
2022
Restoring Eyesight in the Developing World: Dr. Sanduk Ruit on The Long Run
Today’s guest on The Long Run is Dr. Sanduk Ruit. He is an ophthalmologist and the founder and executive director of the Tilganga Institute of Ophthalmology. The institute is in Kathmandu, Nepal. Dr. Ruit has restored the eyesight of more than 130,000 people in Asia and Africa. He’s the pioneer of a small-incision form of cataract surgery. Not only was... Read More